Significantly, overexpression of FGFR2 indicated a poor disease-specific survival of patients (right panel, Fig. 1e) and correlated with several clinicopathologic parameters, implying aberrant FGFR2 activation might contribute to advanced stage of GC. The gene discussed is FGFR2; the disease is gastric cancer.